SVB Leerink analyst Marc Goodman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $50 to $75.
Elon Musk Rings Caution Bell For OpenAI, Microsoft Could ‘Cut Off’ Ties At Any Point
Elon Musk, during the All-In Summit, voiced concerns about Microsoft's significant influence over OpenAI, suggesting that the tech giant could "cut off" ChatGPT anytime.